How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?
Authors:
- Yara Dadalti FragosoYFYara Dadalti Fragoso
- Tarso AdoniTATarso Adoni
- Andrea AnacletoAAAndrea Anacleto
- Joseph Bruno Bidin BrooksJBJoseph Bruno Bidin Brooks
- Margarete de Jesus CarvalhoMCMargarete de Jesus Carvalho
- Rinaldo ClaudinoRCRinaldo Claudino
- Alfredo DamascenoADAlfredo Damasceno
- Maria Lucia Brito FerreiraMFMaria Lucia Brito Ferreira
- Paulo Diniz da GamaPGPaulo Diniz da Gama
- Marcus Vinicus Magno GoncalvesMGMarcus Vinicus Magno Goncalves
- Anderson Kuntz GrzesiukAGAnderson Kuntz Grzesiuk
- Andre Palma da Cunha MattaAMAndre Palma da Cunha Matta
- 22 September 2014
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 14 (11) , 1251-1260
Abstract
Tuberculosis continues to be a serious health problem worldwide. The disease continues to be underdiagnosed and not properly treated. In conditions that affect the immune system, such as multiple sclerosis (MS), latent tuberculosis may thrive and reactivate during the use of immunomodulatory and immunosuppressive drugs. Among the best treatment options for patients with latent or active tuberculosis who have MS are IFN-β, glatiramer acetate and mitoxantrone. Drugs leading to a reduced number and/or function of lymphocytes should be avoided or used with caution. Tuberculosis must always be investigated in patients with MS and treated with rigor.Keywords
This publication has 86 references indexed in Scilit:
- Making wider use of the world's most widely used vaccine: Bacille Calmette–Guérin revaccination reconsideredJournal of The Royal Society Interface, 2013
- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringThe Lancet Neurology, 2011
- TuberculosisThe Lancet, 2011
- H-2 alleles contribute to antigen 85-specific interferon-gamma responses during Mycobacterium tuberculosis infectionCellular Immunology, 2011
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- Tuberculous Granuloma Induction via Interaction of a Bacterial Secreted Protein with Host EpitheliumScience, 2010
- Systems biology approaches to understanding mycobacterial survival mechanismsDrug Discovery Today: Disease Mechanisms, 2010
- Three Mycobacterium tuberculosis Rel Toxin-Antitoxin Modules Inhibit Mycobacterial Growth and Are Expressed in Infected Human MacrophagesJournal of Bacteriology, 2009
- Disclosure of the mycobacterial outer membrane: Cryo-electron tomography and vitreous sections reveal the lipid bilayer structureProceedings of the National Academy of Sciences, 2008
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998